Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.

Qi WX, Tang LN, Sun YJ, He AN, Lin F, Shen Z, Yao Y.

Ann Oncol. 2013 Dec;24(12):2943-52. doi: 10.1093/annonc/mdt292. Epub 2013 Aug 6.

2.
3.
4.

Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.

Qi WX, Shen Z, Tang LN, Yao Y.

Crit Rev Oncol Hematol. 2014 Nov;92(2):71-82. doi: 10.1016/j.critrevonc.2014.04.004. Epub 2014 May 2. Review.

PMID:
24878433
5.

Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.

Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y.

Crit Rev Oncol Hematol. 2014 Mar;89(3):394-403. doi: 10.1016/j.critrevonc.2013.10.002. Epub 2013 Oct 12. Review.

PMID:
24182420
6.

Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.

Zhang ZF, Wang T, Liu LH, Guo HQ.

PLoS One. 2014 Mar 12;9(3):e90135. doi: 10.1371/journal.pone.0090135. eCollection 2014. Review.

8.

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.

Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, Choueiri TK.

Crit Rev Oncol Hematol. 2013 Jul;87(1):80-9. doi: 10.1016/j.critrevonc.2012.12.006. Epub 2013 Jan 12. Review.

PMID:
23317774
9.

Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.

Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, Choueiri TK.

Crit Rev Oncol Hematol. 2015 Mar;93(3):257-76. doi: 10.1016/j.critrevonc.2014.11.006. Epub 2014 Nov 27. Review.

PMID:
25523486
10.

Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.

Peng L, Bu Z, Zhou Y, Ye X, Liu J, Zhao Q.

Tumour Biol. 2014 Sep;35(9):9419-27. doi: 10.1007/s13277-014-2189-1. Epub 2014 Jun 24.

PMID:
24957040
11.

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Je Y, Schutz FA, Choueiri TK.

Lancet Oncol. 2009 Oct;10(10):967-74. doi: 10.1016/S1470-2045(09)70222-0. Epub 2009 Sep 18. Review.

PMID:
19767240
12.

Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.

Hang XF, Xu WS, Wang JX, Wang L, Xin HG, Zhang RQ, Ni W.

Eur J Clin Pharmacol. 2011 Jun;67(6):613-23. doi: 10.1007/s00228-010-0988-x. Epub 2011 Jan 18.

PMID:
21243343
13.
14.

The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.

Li J, Huang S, Zheng W, Ding H, Zhang Y, Huang S, Zhang Z, Chen B, Liang Z, He G, Xiao X, Li S, Xu T, Chen X.

Curr Med Res Opin. 2013 Dec;29(12):1691-9. doi: 10.1185/03007995.2013.836080. Epub 2013 Sep 23. Review.

PMID:
23981081
15.

Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.

Qi WX, Min DL, Shen Z, Sun YJ, Lin F, Tang LN, He AN, Yao Y.

Int J Cancer. 2013 Jun 15;132(12):2967-74. doi: 10.1002/ijc.27979. Epub 2012 Dec 27. Review.

16.

Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.

Sivendran S, Liu Z, Portas LJ Jr, Yu M, Hahn N, Sonpavde G, Oh WK, Galsky MD.

Cancer Treat Rev. 2012 Nov;38(7):919-25. doi: 10.1016/j.ctrv.2012.05.001. Epub 2012 May 30. Review.

PMID:
22651902
17.

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.

Hong S, Fang W, Liang W, Yan Y, Zhou T, Qin T, Wu X, Ma Y, Zhao Y, Yang Y, Hu Z, Xue C, Hou X, Chen Y, Huang Y, Zhao H, Zhang L.

Onco Targets Ther. 2014 Oct 7;7:1851-67. doi: 10.2147/OTT.S68386. eCollection 2014.

18.

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G.

Crit Rev Oncol Hematol. 2015 May;94(2):228-37. doi: 10.1016/j.critrevonc.2014.12.008. Epub 2014 Dec 19. Review.

PMID:
25577572
19.

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK.

Br J Cancer. 2015 Jan 20;112(2):296-305. doi: 10.1038/bjc.2014.564. Epub 2014 Nov 6.

20.

Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.

Qi WX, Tang LN, He AN, Yao Y, Shen Z.

Respir Med. 2013 Aug;107(8):1280-3. doi: 10.1016/j.rmed.2013.06.005. Epub 2013 Jun 28. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk